Rising Cancer Prevalence Spurs Growth In The Chemotherapy-Induced Nausea And Vomiting (CINV) Market: The Driving Engine Behind Chemotherapy-Induced Nausea and Vomiting (CINV) Market Evolution in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size Growth Forecast: What to Expect by 2025?
In recent times, the market encompassing chemotherapy-induced nausea and vomiting treatments has witnessed substantial expansion, projected to increase its valuation from $2.92 billion in 2024 to $3.13 billion in 2025, reflecting a compound annual growth rate of 7.4% over the forecast period; this robust ascent during the past has been fueled by several factors, including a greater utilization of chemotherapy, advancements in medications designed to combat emesis, the implementation of established clinical protocols, and heightened awareness campaigns driven by patient support groups.

How Will the Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size Evolve and Grow by 2029?
Encompassing the upcoming years, the market concerned with chemotherapy-induced nausea and vomiting (CINV) anticipates considerable expansion, with its valuation projected to reach $4.19 billion by 2029, reflecting a robust compound annual growth rate (CAGR) of 7.5%; this upward trajectory is fundamentally driven by developments such as the adoption of personalized medicine approaches, innovations in medications designed to prevent vomiting, the increasing utilization of telehealth and remote patient observation systems, and concerted efforts toward health equity goals. Furthermore, key developments shaping this period are anticipated to involve the deployment of combined antiemetic treatment regimens, the enhancement of supportive care options, the integration of various digital health technologies, and a greater emphasis on post-treatment survivorship care.

View the full report here:
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report

What Drivers Are Propelling the Growth of Chemotherapy-Induced Nausea and Vomiting (CINV) Market Forward?
The escalating incidence of cancer is projected to be the primary catalyst for the expansion of the market related to chemotherapy-induced nausea and vomiting (CINV). Cancer represents an abnormal and invasive growth of certain bodily cells across various bodily locations. With the continuous rise in cancer diagnoses, there is a burgeoning need for improved, more precise anti-emetic interventions designed to mitigate CINV, which is a highly unpleasant consequence of chemotherapy. This intensified concentration on controlling CINV has spurred innovation in comprehending its root causes and formulating cutting-edge treatments. To illustrate, data from the American Cancer Society (ACS), a voluntary US health entity dedicated to eliminating cancer, indicated that for 2023, the United States was expected to see around 1.9 million new cancer diagnoses, translating to roughly 5,370 daily occurrences, alongside an estimated 609,820 fatalities, which averages about 1,670 per day. Consequently, the expanding rate of cancer incidence directly fuels the trajectory of the chemotherapy-induced nausea and vomiting (CINV) market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp

Which Emerging Trends Are Transforming the Chemotherapy-Induced Nausea and Vomiting (CINV) Market in 2025?
Key industry participants within the chemotherapy-induced nausea and vomiting (CINV) sector are proactively developing novel therapeutic solutions, exemplified by fixed intravenous antiemetics, as a strategic move to bolster their market positions. This type of medication involves a set dosage delivered intravenously, aimed at proactively managing or alleviating the sickness and vomiting often associated with cancer treatments or surgical recovery. Illustratively, in January of 2023, Glenmark Pharmaceuticals Limited, a corporation rooted in India specializing in pharmaceuticals, generics, and consumer health items, launched AKYNZEO I.V. across India; notably, this represented the inaugural fixed intravenous antiemetic preparation specifically engineered for the prophylaxis of CINV. The formulation integrates netupitant alongside palonosetron, thereby addressing both the immediate and subsequent phases of emesis, providing the advantages of a single administration, superior rates of full symptom control, and an elevated standard of living for those undergoing cancer therapy, with clinical evidence indicating significant efficacy particularly for individuals receiving chemotherapy regimens known to induce severe emetogenicity.

What Are the Key Segments in the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?
The chemotherapy-induced nausea and vomiting (cinv)market covered in this report is segmented -

1) By Form: Injectables; Oral; Transdermal Patches
2) By Drug Class: 5-HT3 Receptor Antagonists; Neurokinin-1 Receptor Antagonists; Corticosteroids; s; Other Drug Class
3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC); Moderately Emetogenic Chemotherapy (MEC); Low Emetogenic Chemotherapy (LEC)
4) By Distribution Channel: CINV Hospitals; Cancer Research Institute; Retail Pharmacies; Online Pharmacies; Drug Stores
5) By Application: Gynecology; Urology; Gastrointestinal Surgery; Other Applications

Subsegments:
1) By Injectables: Intravenous (IV) Solutions; Intramuscular (IM) Injections
2) By Oral: Tablets; Capsules; Liquid Formulations
3) By Transdermal Patches: Fentanyl Patches; Scopolamine Patches

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13031&type=smp

Who Are the Key Players Shaping the Chemotherapy-Induced Nausea and Vomiting (CINV) Market's Competitive Landscape?
Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals PLC, Ono Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.

What Geographic Markets Are Powering Growth in the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?
North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2024. The regions covered in chemotherapy-induced nausea and vomiting (CINV) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13031

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.